

### **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

#### ***Listing of Claims***

1. **(currently amended)** A method for treating ~~a solid cancerous tumor~~ lung cancer or pancreatic cancer, which comprises administering to a mammal in need of such treatment an ~~effective~~ amount of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) or a pharmaceutically acceptable salt thereof in a range of 500-4900 mg/m<sup>2</sup> and administering an effective amount of gemcitabine, wherein the DMXAA or the pharmaceutically acceptable salt thereof and the gemcitabine are administered in a ~~potentiating~~ ratio in the range of 1:15 to 1:10 (DMXAA:gemcitabine).

2. **(canceled)**

3. **(previously presented)** The method according to claim 1 wherein the DMXAA or pharmaceutically acceptable salt thereof and gemcitabine are administered concomitantly.

4. **(currently amended)** A method for treating ~~a solid cancerous tumor~~ lung cancer or pancreatic cancer, which comprises administering to a mammal in need of such treatment an ~~effective~~ amount of DMXAA or pharmaceutically acceptable salt thereof in a range of 500-4900 mg/m<sup>2</sup> and administering an effective amount of gemcitabine, wherein the DMXAA or pharmaceutically acceptable salt thereof and the gemcitabine are administered sequentially in a ratio in the range of 1:15 to 1:10.

5-6. **(canceled)**

7. **(currently amended)** A pharmaceutical ~~dosage combination~~ for treating ~~a solid cancerous tumor~~ lung cancer or pancreatic cancer comprising DMXAA or a pharmaceutically acceptable salt thereof in ~~an amount to provide~~ a dosage in a range of 500 to 4900 mg/m<sup>2</sup> and gemcitabine in a ~~potentiating~~ ratio in the range of 1:15 to 1:10 in a mammal.

8-10. **(canceled)**

11. **(currently amended)** A pharmaceutical formulation comprising ~~a potentiating ratio of~~ DMXAA or a pharmaceutically acceptable salt thereof in an amount in a range of 500-4900 mg/m<sup>2</sup> and gemcitabine, in a ratio in the range of 1:15 to 1:10, in association with one or more pharmaceutically acceptable carriers therefor.

12. **(previously presented)** The pharmaceutical formulation according to claim 11 wherein the formulation is adapted for intravenous administration.

13-15. **(canceled)**

16. **(currently amended)** A process for the preparation of a pharmaceutical formulation which process comprises bringing into association ~~a potentiating ratio of~~ DMXAA or a pharmaceutically acceptable salt thereof in an amount in a range of 500-4900 mg/m<sup>2</sup> and gemcitabine, in a ratio in the range of 1:15 to 1:10, with one or more pharmaceutically acceptable carriers therefor.

17-19. **(canceled)**

20. **(currently amended)** A kit comprising in association for separate administration ~~a potentiating ratio of~~ DMXAA or a pharmaceutically acceptable salt thereof in an amount in a range of 500-4900 mg/m<sup>2</sup> and gemcitabine, in a ratio in the range of 1:15 to 1:10.

21-28. **(canceled)**